Publications by authors named "Miwa Fujihara"
Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it is especially effective for MBC with resistance to trastuzumab. Although several reports have described T-DM1 resistance, few have examined the mechanism underlying T-DM1 resistance after the development of acquired resistance to trastuzumab. We previously reported that YES1, a member of the Src family, plays an important role in acquired resistance to trastuzumab in -amplified breast cancer cells.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed 387 patients who had implant-based breast reconstruction between 2004 and 2017, focusing on local recurrence and related risk factors.
- The local recurrence rate was found to be 3.1%, mainly caused by palpable masses, with lymphatic vessel invasion and inadequate vertical margins identified as significant risk factors.
- Findings suggest that surgical intervention and adjuvant radiation therapy can lead to positive outcomes for patients experiencing local recurrence after the reconstruction.
Article Synopsis
- This phase II study aimed to assess the effectiveness of combining nab-paclitaxel (nab-PTX) with anthracycline-based therapy as a neoadjuvant treatment for advanced breast cancer.
- A total of 41 patients were treated, with observable pathological complete response (pCR) rates varying significantly among different breast cancer subtypes, with a total pCR of 24% overall but as high as 100% for HER2-positive cases.
- The treatment was generally well-tolerated, although notable side effects included peripheral sensory neuropathy and neutropenia, with one patient experiencing fatal complications linked to pneumonia.
Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution.
View Article and Find Full Text PDF